NeuroMolecular Medicine

, Volume 12, Issue 3, pp 224–228 | Cite as

No Association of VEGF Polymorphims with Alzheimer’s Disease

  • Sara LandgrenEmail author
  • Mona Seibt Palmér
  • Ingemar Skoog
  • Lennart Minthon
  • Anders Wallin
  • Niels Andreasen
  • Madeleine Zetterberg
  • Kaj Blennow
  • Henrik Zetterberg
Original Paper


The vascular hypothesis of Alzheimer’s disease (AD) has brought the vascular endothelial growth factor (VEGF) into focus. The genomic region including the VEGF gene has been linked to AD and single nucleotide polymorphisms (SNPs) of the VEGF have in previous studies been associated with AD risk. To further evaluate these findings, we genotyped two SNPs in the VEGF gene (rs699947 [−2578]) and rs1570360 [−1154]) by TaqMan Allelic Discrimination in a study sample including AD patients (n = 801) and controls (n = 286). In a subgroup of the population these SNPs were analyzed in relation to APOE ε4 genotype, to cerebrospinal fluid biomarkers (T-tau, P-tau, and β42-Amyloid) as well as to neuropathological markers for AD (neurofibrillary tangles and senile plaques). No significant associations with risk for AD or any of the studied biomarkers could be found in this study, thus not supporting VEGF as being a major risk gene for AD.


Alzheimer’s disease VEGF Tau β-Amyloid 



This work was supported by grants from the Swedish Research Council, the Swedish Society for Medical Research, the Sahlgrenska University Hospital, the Göteborg Medical Society, Swedish Brain Power, Hjalmar Svenssons forskningsfond, Stiftelsen för Gamla Tjänarinnor and Alzheimerfonden.


  1. Altman, D. G. (1991). Practical statistics for medical research (1st ed.). London: Chapman & Hall.Google Scholar
  2. Blacker, D., Bertram, L., Saunders, A. J., Moscarillo, T. J., Albert, M. S., Wiener, H., et al. (2003). Results of a high-resolution genome screen of 437 Alzheimer’s disease families. Human Molecular Genetics, 12, 23–32.CrossRefPubMedGoogle Scholar
  3. Blennow, K., Ricksten, A., Prince, J. A., Brookes, A. J., Emahazion, T., Wasslavik, C., et al. (2000). No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer’s disease, and no change in A2M mRNA, protein, or protein expression. Journal of Neural Transmission, 107, 1065–1079.CrossRefPubMedGoogle Scholar
  4. Borroni, B., Ghezzi, S., Agosti, C., Archetti, S., Fenoglio, C., Galimberti, D., et al. (2008). Preliminary evidence that VEGF genetic variability confers susceptibility to frontotemporal lobar degeneration. Rejuvenation Research, 11, 773–780.CrossRefPubMedGoogle Scholar
  5. Cao, L., Jiao, X., Zuzga, D. S., Liu, Y., Fong, D. M., Young, D., et al. (2004). VEGF links hippocampal activity with neurogenesis, learning and memory. Nature Genetics, 36, 827–835.CrossRefPubMedGoogle Scholar
  6. Casserly, I., & Topol, E. (2004). Convergence of atherosclerosis and Alzheimer’s disease: Inflammation, cholesterol, and misfolded proteins. Lancet, 363, 1139–1146.CrossRefPubMedGoogle Scholar
  7. Chapuis, J., Tian, J., Shi, J., Bensemain, F., Cottel, D., Lendon, C., et al. (2006). Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer’s disease. Neurobiology of Aging, 27, 1212–1215.CrossRefPubMedGoogle Scholar
  8. Chiappelli, M., Borroni, B., Archetti, S., Calabrese, E., Corsi, M. M., Franceschi, M., et al. (2006). VEGF gene and phenotype relation with Alzheimer’s disease and mild cognitive impairment. Rejuvenation Research, 9, 485–493.CrossRefPubMedGoogle Scholar
  9. Del Bo, R., Scarlato, M., Ghezzi, S., Martinelli Boneschi, F., Fenoglio, C., Galbiati, S., et al. (2005). Vascular endothelial growth factor gene variability is associated with increased risk for AD. Annals of Neurology, 57, 373–380.CrossRefPubMedGoogle Scholar
  10. Farkas, E., & Luiten, P. G. (2001). Cerebral microvascular pathology in aging and Alzheimer’s disease. Progress in Neurobiology, 64, 575–611.CrossRefPubMedGoogle Scholar
  11. Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., De Deyn, P. P., et al. (1999). Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology, 52, 1555–1562.PubMedGoogle Scholar
  12. Johansson, A., Katzov, H., Zetterberg, H., Feuk, L., Johansson, B., Bogdanovic, N., et al. (2004). Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer’s disease. Human Genetics, 114, 581–587.CrossRefPubMedGoogle Scholar
  13. Kalaria, R. N., Cohen, D. L., Premkumar, D. R., Nag, S., LaManna, J. C., & Lust, W. D. (1998). Vascular endothelial growth factor in Alzheimer’s disease and experimental cerebral ischemia. Brain Research. Molecular Brain Research, 62, 101–105.CrossRefPubMedGoogle Scholar
  14. Kim, Y., Nam, Y. J., & Lee, C. (2006). Haplotype analysis of single nucleotide polymorphisms in VEGF gene for vascular dementia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 141B, 332–335.CrossRefGoogle Scholar
  15. Livak, K. J. (1999). Allelic discrimination using fluorogenic probes and the 5’ nuclease assay. Genetic Analysis, 14, 143–149.PubMedGoogle Scholar
  16. Mateo, I., Llorca, J., Infante, J., Rodriguez-Rodriguez, E., Fernandez-Viadero, C., Pena, N., et al. (2007). Low serum VEGF levels are associated with Alzheimer’s disease. Acta Neurologica Scandinavica, 116, 56–58.CrossRefPubMedGoogle Scholar
  17. Mateo, I., Llorca, J., Infante, J., Rodriguez-Rodriguez, E., Sanchez-Quintana, C., Sanchez-Juan, P., et al. (2006). Case–control study of vascular endothelial growth factor (VEGF) genetic variability in Alzheimer’s disease. Neuroscience Letters, 401, 171–173.CrossRefPubMedGoogle Scholar
  18. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939–944.PubMedGoogle Scholar
  19. Stevens, A., Soden, J., Brenchley, P. E., Ralph, S., & Ray, D. W. (2003). Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Research, 63, 812–816.PubMedGoogle Scholar
  20. Storkebaum, E., & Carmeliet, P. (2004). VEGF: A critical player in neurodegeneration. Journal of Clinical Investigation, 113, 14–18.PubMedGoogle Scholar
  21. Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjogren, M., et al. (2000). Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neuroscience Letters, 285, 49–52.CrossRefPubMedGoogle Scholar
  22. Yang, S. P., Bae, D. G., Kang, H. J., Gwag, B. J., Gho, Y. S., & Chae, C. B. (2004). Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer’s disease. Neurobiology of Aging, 25, 283–290.CrossRefPubMedGoogle Scholar
  23. Yuan, Q., Zuo, X., & Jia, J. (2009). Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer’s disease among Northern Chinese Han. Neuroscience Letters, 457, 133–136.CrossRefPubMedGoogle Scholar
  24. Zetterberg, H. (2008). Biomarkers reflecting different facets of Alzheimer’s disease. European Journal of Neurology, 15, 1143–1144.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Sara Landgren
    • 1
    Email author
  • Mona Seibt Palmér
    • 2
  • Ingemar Skoog
    • 3
  • Lennart Minthon
    • 4
  • Anders Wallin
    • 3
  • Niels Andreasen
    • 5
  • Madeleine Zetterberg
    • 6
  • Kaj Blennow
    • 3
  • Henrik Zetterberg
    • 3
  1. 1.Department of Pharmacology, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
  2. 2.Department of Clinical Chemistry and Transfusion Medicine, Institute of BiomedicineThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
  3. 3.Department of Psychiatry and Neurochemistry, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgMölndalSweden
  4. 4.Clinical Memory Research Unit, Department of Clinical SciencesLund UniversityMalmöSweden
  5. 5.Memory Clinic M51, Department of Geriatric Medicine, Institute of NeurobiologyCaring Sciences and Society, Karolinska HospitalHuddingeSweden
  6. 6.Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgMölndalSweden

Personalised recommendations